Brief: Sorrento Completes Successfully SAD Study And Initiates MAD Phase 1 Study With STI-1558
03/08/2022 14:12
Aug 3 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO COMPLETES SUCCESSFULLY THE SAD STUDY AND
INITIATES THE
MAD PHASE 1 STUDY WITH STI-1558, AN ORAL M(PRO) INHIBITOR AS A
STANDALONE TREATMENT AND PREVENTION OF COVID-19 WITHOUT THE
RITONAVIR AS BOOSTER
* SORRENTO THERAPEUTICS INC- INITIATION OF MULTIPLE
ASCENDING DOSE
(MAD) PORTION OF STI-1558 STUDY HAS BEEN INITIATED
* SORRENTO THERAPEUTICS INC- PRELIMINARY OVERALL SUMMARY OF
TREATMENT-EMERGENT ADVERSE EVENTS SHOWED THAT THERE WERE NO
SERIOUS AES OR SEVERE TEAES
Source text for Eikon: ID:nGNX58KwfB
Further company coverage: SRNE.O
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20